Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial

Treatment with the tested SCIT-product at a dose of 50,000 AUeq/mL was safe and well tolerated. The primary outcome was not met, with no significant difference observed between the active and placebo groups. A likely explanation might be the inclusion of mainly patients with mild symptoms of rhino conjunctivitis (539 of in total 767 randomized subjects). Post hoc analysis, however, indicated that SCIT was effective in the subgroup of patients with moderate to severe disease, suggesting that the overall study outcome may have been influenced by the inclusion of a large proportion of patients with only mild symptoms of HDM-induced rhino-conjunctivitis. As a consequence, reconfirming efficacy requires adequate baseline symptom severity, especially in HDM allergic patients.

Authors

Institutions

Publication Details

Journal
Allergy
Published
2025-09-18
DOI
https://doi.org/10.1111/all.70063
Citations
1
Primary Topic
Allergic Rhinitis and Sensitization
Type
article
Field-Weighted Citation Impact
1.62

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial

Andrzej Bożek, Oliver Pfaar, Ronald van Ree, Rimko ten Have et al.
1 citations
Allergy
Allergic Rhinitis and Sensitization
1.62
article

Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial

Andrzej Bożek, Oliver Pfaar, Ronald van Ree, Rimko ten Have, Margitta Worm, Claus Bachert, Marek Jutel, Donghui Yu, Annemie Narkus, Andreas Distler, Dirk-Jan E. Opstelten, Hans Hoogeveen
article en
1 citations

Abstract

Treatment with the tested SCIT-product at a dose of 50,000 AUeq/mL was safe and well tolerated. The primary outcome was not met, with no significant difference observed between the active and placebo groups. A likely explanation might be the inclusion of mainly patients with mild symptoms of rhino conjunctivitis (539 of in total 767 randomized subjects). Post hoc analysis, however, indicated that SCIT was effective in the subgroup of patients with moderate to severe disease, suggesting that the overall study outcome may have been influenced by the inclusion of a large proportion of patients with only mild symptoms of HDM-induced rhino-conjunctivitis. As a consequence, reconfirming efficacy requires adequate baseline symptom severity, especially in HDM allergic patients.

AllergyVol. 80(12)
National Archives and Records Administration (US), Philipps University of Marburg (DE), Medical University of Silesia (PL), Wroclaw Medical University (PL), Augenstern (DE), Clinical Research Center for Hair and Skin Science (DE), HAL Allergy (Netherlands) (NL), GGZ inGeest (NL), Amsterdam University Medical Centers (NL), Charité - Universitätsmedizin Berlin (DE)
Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu
Openalex Percentile: Top 15%
Allergic Rhinitis and Sensitization
1.62
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial — Andrzej Bożek, Oliver Pfaar, et al. · Allergy (2025) | TGRS Research Map | TGRS